Influence of Supercritical Antisolvent Micronization Parameters on Nalmefene HCl Powder Characteristics

Advanced Powder Technology

Volumn 19, Issue 6, 2008, Pages 523-540

  Adami, R ^a,b   Jarvenpaa E ^a   Osséo, L Sesti ^b   Huopalahti, R ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

anhydrous; hydrate; micronization; nalmefene HCl; pseudo polymorphism; Supercritical antisolvent

Indexed keywords

CARBON DIOXIDE; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; DEGRADATION; DIFFERENTIAL SCANNING CALORIMETRY; ETHANOL; GAS CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; HYDRATION; LIQUID CHROMATOGRAPHY; PHOTODEGRADATION; POLYMORPHISM; POWDERS; SOLVENTS; SUPERCRITICAL FLUID EXTRACTION; SYNTHETIC APERTURE SONAR; X RAY DIFFRACTION ANALYSIS;

ANHYDROUS; HYDRATE; MICRONIZATION; NALMEFENE HCL; PSEUDO-POLYMORPHISM; SUPERCRITICAL ANTISOLVENT;

ORGANIC SOLVENTS;

EID: 59349098196     PISSN: 09218831     EISSN: 15685527     Source Type: Journal    
DOI: 10.1163/156855208X368607     Document Type: Article

References (36)

1. York P. Solid-state properties of powders in the formulation and processing of solid dosage forms. Int. J. Pharm. 14 (1983) 1-28
2. Marshall P.V., and York P. Crystallization solvent induced solid-state and particulate modifications of nitrofurantoin. Int. J. Pharm. 55 (1989) 257-263
3. Khankari R.K., and Grant D.J.W. Pharmaceutical hydrates. Thermochim. Acta 248 (1995) 61-79
4. Hancock B.C., and Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 (1997) 1-12
5. Reverchon E. Supercritical antisolvent precipitation of micro- and nano-particles. J. Supercrit. Fluids 15 (1999) 1-21
6. Jung J., and Perrut M. Particle design using supercritical fluids: literature and patent survey. J. Supercrit. Fluids 20 (2001) 179-219
7. Thiering R., Dehghani F., and Foster N.R. Current issues relating to anti-solvent micronisation techniques and their extension to industrial scales. J. Supercrit. Fluids 21 (2001) 159-177
8. Shariati A., and Peters C.J. Recent developments in particle design using supercritical fluids. Curr. Opin. Solid State Mater. 7 (2003) 371-383
9. Hakuta Y., Hayashi H., and Arai K. Fine particle formation using supercritical fluids. Curr. Opin. Solid State Mater. 7 (2003) 341-351
10. Yeo S.-D., and Kiran E. Formation of polymer particles with supercritical fluids: a review. J. Supercrit. Fluids 34 (2005) 287-308
11. Reverchon E., and Adami R. Nanomaterials and supercritical fluids. J. Supercrit. Fluids 37 (2006) 1-22
12. 2. J. Therm. Anal. Calorim. 77 (2004) 625-638
13. Bettini R., Bonassi L., Castoro V., Rossi A., Zema L., Gazzaniga A., and Giordano F. Solubility and conversion of carbamazepine polymorphs in supercritical carbon dioxide. Eur. J. Pharm. Sci. 13 (2001) 281-286
14. 2. Pharm. Res. 18 (2001) 682-688
15. De Gioannis B., Jestin P., and Subra P. Morphology and growth control of griseofulvin recrystallized by compressed carbon dioxide as antisolvent. J. Cryst. Growth 262 (2004) 519-526
16. Michel M.E., Bolger G., and Weissman B.A. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Finds Exp. Clin. Pharmacol. 7 (1985) 175-177
17. Mason B.J., Ritvo E.C., Morgan R.O., Salvato F.R., Goldberg G., Welch B., and Mantero-Atienza E. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol. Clin. Exp. Res. 18 (1994) 1162-1167
18. Murthy S.S., and Brittain H.G. Stability of Revex, nalmefene hydrochloride injection, in injectable solutions. J. Pharmaceut. Biomed. 15 (1996) 221-226
19. Meyer M.C., Straughn A.B., Lo M.W., Schary W.L., and Whitney C.C. Bioequivalence, dose- proportionality, and pharmacokinetics of naltrexone after oral administration. J. Clin. Psychiat. 45 (1984) 15-19
20. Gal T.J., DiFazio C.A., and Dixon R. Prolonged blockade of opioid effect with oral nalmefene. Clin. Pharmacol. Ther. 40 (1986) 537-542
21. Dixon R., Gentile J., Hsu H.B., Hsiao J., Howes J., Garg D., and Weidler D. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J. Clin. Pharmacol. 27 (1987) 233-239
22. Gonzalez J.P., and Brogden R.N. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35 (1988) 192-213
23. Xie S., Suckow R.F., Mason B.J., Allen D., and Cooper T.B. Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry. J. Chromatogr. B 773 (2002) 143-149
24. June H.L., Grey C., Warren-Reese C., Durr L.F., Ricks-Cord A., Johnson A., McCane S., Williams L., Mason D., Cummings R., and Lawrence A. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol. Clin. Exp. Res. 22 (1998) 2174-2185
25. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., and Cutler R.B. A double-blind, placebo- controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry 56 (1999) 719-724
26. June H.L., Cummings R., Eiler W.J.A., Foster K.L., McKay P.F., Seyoum R., Garcia M., McCane S., Grey C., Hawkins S.E., and Mason D. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol- preferring (P) rats. Neuropsychopharmacology 29 (2004) 285-299
27. R. L. Hale, C. C. Hodges, P. M. Lloyd, A. T. Lu, D. J. Myers, J. D. Rabinowitz and M. J. Wensley, Drug condensation aerosols and kits, US A1 2004099269 (2004).
28. M. Xia and T. Zhang, Manufacture of nasal medicine containing nalmefene hydrochloride, CN A 1634062 (2005).
29. Adami R., Reverchon E., Jarvenpaa E., and Huopalahti R. Supercritical antisolvent micronization of nalmefene HCl on laboratory and pilot scale. Powder Technol. 182 (2008) 105-112
30. Reverchon E., Celano C., Della Porta G., Di Trolio A., and Pace S. Supercritical antisolvent precipitation: a new technique for preparing submicronic yttrium powders to improve YBCO superconductors. J. Mater. Res. 13 (1998) 284-289
31. Reverchon E., Della Porta G., Di Trolio A., and Pace S. Supercritical antisolvent precipitation of nanoparticles of superconductor precursors. Ind. Eng. Chem. Res. 37 (1998) 952-958
32. USP 28, Organic Volatiles Impurities, 467, pp. 2322-2332, US Pharmcopeial Convention, Rockville, MD (2005).
33. Federal Register, International Conference on Harmonization. Guidance on Impurities. Residual Solvents. Fed. Regist. 62 (1997) 67377-67388
34. In: O'Neil M.J., Smith A., Heckelman P.E., and Budavari S. (Eds). The Merck Index: an Encyclopedia of Chemicals, Drugs, and Biologicals. 13th edn. (2001), Wiley, New York
35. H. A. Brittain, D. A. Dickason, J. Hotz, S. L. Lyons, M. J. Ramstack and S. G. Wright, Polymorphic forms of naltrexone, WO A2 2004108084 (2004).
36. Giron D., Goldbronn Ch., Mutz M., Pfeffer S., Piechon Ph., and Schwab P. Solid state characterizations of pharmaceutical hydrates. J. Therm. Anal. Calorim. 68 (2002) 453-465